Next Article in Journal
Xyloglucan, Hibiscus and Propolis in the Management of Uncomplicated Lower Urinary Tract Infections: A Systematic Review and Meta-Analysis
Previous Article in Journal
Antifungal Carvacrol Loaded Chitosan Nanoparticles
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 11
Issue 1
10.3390/antibiotics11010012
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Exploring the Nature of the Antimicrobial Metabolites Produced by Paenibacillus ehimensis Soil Isolate MZ921932 Using a Metagenomic Nanopore Sequencing Coupled with LC-Mass Analysis

by
Mohamed A. Eltokhy
1,
Bishoy T. Saad
2,
Wafaa N. Eltayeb
1,
Ibrahim S. Yahia
3,4,5,
Khaled M. Aboshanab
6,* and
Mohamed S. E. Ashour
7
1
Department of Microbiology, Faculty of Pharmacy, Misr International University (MIU), Cairo 19648, Egypt
2
Department of Bioinformatics, HITS Solutions Co., Cairo 11765, Egypt
3
Laboratory of Nano-Smart Materials for Science and Technology (LNSMST), Department of Physics, Faculty of Science, King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia
4
Research Center for Advanced Materials Science (RCAMS), King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia
5
Nanoscience Laboratory for Environmental and Biomedical Applications (NLEBA), Semiconductor Lab., Department of Physics, Faculty of Education, Ain Shams University, Roxy, Cairo 11757, Egypt
6
Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, Organization of African Unity Str., Cairo 11566, Egypt
7
Department of Microbiology and Immunology, Faculty of Pharmacy, Al-Azhar University, Cairo 11651, Egypt
*
Author to whom correspondence should be addressed.
Antibiotics 2022, 11(1), 12; https://doi.org/10.3390/antibiotics11010012
Submission received: 6 December 2021 / Revised: 19 December 2021 / Accepted: 20 December 2021 / Published: 22 December 2021
Browse Figures
Versions Notes

Abstract

:
The continuous emergence of multidrug-resistant (MDR) pathogens poses a global threat to public health. Accordingly, global efforts are continuously conducted to find new approaches to infection control by rapidly discovering antibiotics, particularly those that retain activities against MDR pathogens. In this study, metagenomic nanopore sequence analysis coupled with spectroscopic methods has been conducted for rapid exploring of the various active metabolites produced by Paenibacillus ehimensis soil isolate. Preliminary soil screening resulted in selection of a Gram-positive isolate identified via 16S ribosomal RNA gene sequencing as Paenibacillus ehimensis MZ921932. The isolate showed a broad range of activity against MDR Gram-positive, Gram-negative, and Candida spp. A metagenomics sequence analysis of the soil sample harboring Paenibacillus ehimensis isolate MZ921932 (NCBI GenBank accession PRJNA785410) revealed the presence of conserved biosynthetic gene clusters of petrobactin, tridecaptin, locillomycin (β-lactone), polymyxin, and macrobrevin (polyketides). The liquid chromatography/mass (LC/MS) analysis of the Paenibacillus ehimensis metabolites confirmed the presence of petrobactin, locillomycin, and macrobrevin. In conclusion, Paenibacillus ehimensis isolate MZ921932 is a promising rich source for broad spectrum antimicrobial metabolites. The metagenomic nanopore sequence analysis was a rapid, easy, and efficient method for the preliminary detection of the nature of the expected active metabolites. LC/MS spectral analysis was employed for further confirmation of the nature of the respective active metabolites.

1. Introduction

The increased emergence of antibiotic resistance among microbes poses a worldwide threat. Hence, there is an urgent need for discovery of new antimicrobials. Soil microbial diversity is a very rich source of microorganisms that produce secondary metabolites possessing antimicrobial activity. Selman Waksman, a leader in antibiotic discovery, organized a study that has led to the discovery of streptomycin [1]. The later antibiotic was isolated from Actinomyces griseus [2]. Another example was the isolation of gramicidin from Bacillus brevis [3]. During the golden age of antibiotic discovery between 1940 and 1950, novel antibiotics were easily discovered by random conventional screening methods. However, random screening methods proved to be time consuming and tedious; as an example, daptomycin was obtained by screening one to ten million Actinomycetes isolates. Herein, new advanced methods for discovery of novel antibiotics are a global necessity to discover novel antimicrobial agents to combat multidrug-resistant microorganisms [4].
Through the years of the 1960s and 1980s, several antibiotic classes were developed and used, but later, the lucrative progress of new antimicrobials has been hindered. On the other side, continuous evolution of bacterial resistance developed, resulting in serious incurable bacterial infections imposing a public health threat. Further progress in this area requires multidisciplinary studies including structural biology, enzymology, bioinformatics, metabolomics, transcriptomics, proteomics, and advances in mass spectral analysis, and it is believed that this will lead to the “second golden age for antibiotics” and natural product detection [5].
The facultative anaerobic Paenibacillus is a motile, endospore-forming bacteria found in various habitats. Paenibacillus was previously identified within the genus of Bacillus [6]. However, after the development of molecular identification techniques, later in 1993, it was identified as a separate genus and now is under the family Paenibacillaceae. The different species are Gram-variable, as they can be either Gram-positive or Gram-negative [7].
Antimicrobial production varies between species due to the diversity in antimicrobial-encoding genes [8]. The produced antimicrobials by Paenibacillus include peptides, volatile organic compounds, and enzymes [9]. The produced enzyme shows a potent antifungal activity. These enzymes include proteases, cellulases, glucanases, and chitinases [9]. Paenibacillus ehimensis KWN38 bioactive metabolites can break the structure of hypha and stop the growth of Rhizoctonia solani, Phytophthora capsic, and Fusarium oxysporum [9,10]. The chitinase produced by some Paenibacillus spp. is stable with other fungicides, suggesting a potential combination [11].
The produced antimicrobial peptides are of two types: non-ribosomally synthesized peptides and ribosomally-synthesized bacteriocins. It is known that Paenibacillus produces two out of the three classes of bacteriocins [9]. Several species such as Paenibacillus kobensis and Paenibacillus alvei are known to produce polymyxins [9].
A study conducted on Paenibacillus polymyxa (P13) showed antimicrobial activity against Lactobacillus species [12]. The extracted antimicrobial was effective against several Gram-positive and Gram-negative bacteria, showing bacteriocin-like properties, and was stable when heated up to 90 °C. It was also stable at acidic pH, but not at alkaline pH, and it was insensitive to chelators and organic solvents [12].
In the second decade of sequencing, metagenomics analysis was introduced. Metagenomics analysis identifies all DNA present in a given community [13]. Metagenomics made it possible to discover antimicrobials from natural sources [14] as bioinformatics analysis and systematic characterization made it possible to explore the hidden biosynthetic gene clusters [15].
The technological advancement in genome mining and sequencing rejuvenated the examination of under-explored soil environments [16]. The different microbial communities and co-existence in a specific environment influence the evolution of bacteria and genetic expressions. As discovered, bacterial symbionts of marine invertebrates produce several novel natural products. Most bioactive polyketides were isolated from a marine bacterial symbiont called Candidatus Entotheonella sp. with the marine sponge Theonella swinhoei [17]. The Clostridium genus was not affiliated with any form of antimicrobial production until genomic data were studied and investigated. Studying Clostridium cellulolyticum under laboratory conditions revealed no antibiotic production. However, studying conditions that mimic the soil environment by adding aqueous soil extract to the fermentation process prompted the antimicrobial production for closthioamide [18].
The importance of chromatographic methods was highlighted by a study of secondary metabolites extracted from four isolates habituated in industrial wastewater. The purpose of the study was to discover novel antimicrobial agents. The characterization of the targeted elute was performed using reversed phase high-performance column chromatography (RP-HPLC) [19]. Another study characterized antimicrobial compounds obtained from screened fungi that have bioactivity against clinical isolates. The functional group of the compound was characterized using gas chromatography–mass spectrometry (GC–MS) [20].
From the previous studies, we decided to rediscover antimicrobial metabolites production by Paenibacillus genus, isolated from different Egyptian soil samples. The study started by applying conventional preliminary soil phenotypic screening methods. Then, a metagenomic nanopore sequence analysis of the soil sample harboring the promising Paenibacillus genus was carried out to identify the conserved biosynthetic gene clusters of the produced active metabolites. Afterward, LC–mass spectroscopy was conducted to confirm the nature of the respective antimicrobial metabolites.

2. Results

2.1. Screening of the Antimicrobial Activities of the Recovered Bacterial Isolates

Table 1, Table 2 and Table 3 showed the results of the preliminary screening for the antimicrobial activities of the three recovered bacterial isolates, coded SP1, SP2, and SP3, that phenotypically and biochemically belonged to Paenibacillus spp. Each isolate was recovered from a different soil sample. The isolate SP1 showed inhibition against all the tested standard and MDR Gram-positive, Gram-negative, and Candida isolates. Therefore, the soil sample harboring the isolate SP1 was selected for a metagenomic analysis and LC–mass spectral analysis of the produced metabolites.

2.2. Molecular Identification

The16S ribosomal RNA gene sequencing of the isolate coded SP1 revealed 99% identity to NCBI reference sequence of Paenibacillus ehimensis strain IFO 15659. Therefore, the isolate coded SP1 was identified as Paenibacillus ehimensis isolate MZ921932. The 16S ribosomal RNA gene sequence was analyzed and deposited in the National Center of Biotechnology Information (NCBI) GenBank under nucleotide accession number MZ921932.

2.3. The Antimicrobial Activities of the Extracted Metabolite(s) of Paenibacillus ehimensis Isolate MZ921932

Dichloromethane extract showed zones of inhibition against MDR bacteria than the ethyl acetate extract. However, the ethyl acetate extract showed bigger zones of inhibition against tested Candida spp. than the Dichloromethane extract, as shown in Table 4.

2.4. Metagenomics Analysis of the Soil Sample

Results revealed a maximum read count of 600,000 reads, and the mean sequence length was 1000 bp. Sequence length (bp) ranged from 100–10,000 bp. FastQ quality score per base showed good quality (Phred score range between 10 and <25). Percentage N count (ambiguous) was zero, and there were no significant duplicate reads.
Percent abundance of the bacterial phylum present in the soil showed that the most abundant phylum was Achromobacter. The organism with the most abundance was Pseudarthrobacter sp. NIBRBAC000502770, representing 17% of the sample, followed by Arthrobacter phenanthrenivorans sphe3 of 10%. Paenibacillus ehimensis belongs to Firmicutes phylum, which was present in the soil sample with around 15% abundance. Metagenomics sequences were deposited in the NCBI GenBank under accession number PRJNA785410 (https://www.ncbi.nlm.nih.gov/sra/PRJNA785410, accessed on 5 December 2021) and Figure S1 (Supplementary) illustrates the soil microbial diversity.

2.5. Identification of Secondary Metabolite(s) Gene Clusters Paenibacillus ehimensis Isolate MZ921932

2.5.1. Siderophore Petrobactin

The resulted gene cluster showed 83% similarity to the siderophore Petrobactin biosynthetic gene cluster (Figure 1).

2.5.2. Traditional (Multi-)Modular Non-Ribosomal Peptide Synthases

Gene cluster showed 80% similarity to the tridecaptin biosynthetic gene cluster, as displayed in Figure 2.

2.5.3. Hybrid Region: Beta-Lactone Containing Protease Inhibitor and Non-Ribosomal Peptide Fragment

The gene cluster gave 80% similarity to the Locillomycin biosynthetic gene cluster, as depicted in Figure 3.

2.5.4. Traditional (Multi-)Modular Non-Ribosomal Peptide Synthases

Gene cluster gave 42% similarity to Locillomycin biosynthetic gene cluster as depicted in Figure 4.

2.5.5. Hybrid Region: Thioamide-Containing Non-Ribosomal Peptide and Traditional (Multi-)Modular Non-Ribosomal Peptide Synthases

The resulted gene cluster revealed 40% similarity to the biosynthetic gene cluster of Polymyxin A and Polymyxin B, 40% similar to the gene cluster producing Colistin/Colistin B (Figure 5).

2.5.6. Terpene

The resulted gene cluster showed 40% similarity to biosynthetic gene cluster of the produced Carotenoid (Figure 6).

2.5.7. Trans-AT Polyketide

Gene cluster was 20% similar to the gene cluster producing the Difficidin, 20% similar to the gene cluster producing the Macrobrevin, and 13% similar to the gene cluster producing the Sorangicin (Figure 7).

2.5.8. Hybrid Region: Thioamide-Containing Non-Ribosomal Peptide and Traditional (Multi-)Modular Non-Ribosomal Peptide Synthases

The gene cluster showed 60% similarity to the gene cluster of the producing Paenibacterin, 40% similarity to the gene cluster producing the Polymyxin B, the gene cluster producing Tridecaptin, and the gene cluster producing colistin A/colistin B, and 20% similarity to the gene cluster producing Fengycin (Figure 8).

2.6. Characterization of the Antimicrobial Metabolite(s)

2.6.1. TLC Analysis

The spots of the separated compounds were observed under a UV lamp at 365 nm (fluorescence) and 254 nm (absorbance). In case of dichloromethane extract, TLC using solvent system ethyl acetate: methanol (9:1) showed four separated spots, while solvent system ethyl acetate: methylene chloride (9:1) and dichloromethane: ethanol (6.5:3.5) showed no significant separation. Ethyl acetate extract, TLC using solvent system ethyl acetate: methanol (9:1) showed two separated spots, while TLC using solvent system ethyl acetate: methylene chloride (9:1) and dichloromethane: ethanol (6.5:3.5) showed no significant separation (Figure S2).

2.6.2. LC/MS Analysis

Ethyl Acetate Extract

LC/MS carried on cell-free ethyl acetate extract generated 95 peaks in negative ion mode and 96 peaks in positive ion mode, illustrated in Figure 9, and each peak had variable masses (Figure 9).
The mass spectra were analyzed for the detection of the secondary metabolite of Paenibacillus ehimensis isolate MZ921932, as illustrated in Figure 10. (a) Locillomycin (β-lactone) was detected at peak 71 at time 14.12 min with m/z 229.29. (b) Petrobactin was detected at peak 40 at time 8.69 min with m/z 720.663. Macrobrevin was detected at peak 80 at time 17.02 min with m/z 667.507.

Dichloromethane Extract

LC/MS was carried on cell-free dichloromethane extract generated 155 peaks in negative ion mode and 156 peaks in positive ion mode, illustrated in Figure 11.
The mass spectra of the dichloromethane extract were analyzed for the detection of the secondary metabolite of Paenibacillus ehimensis isolate MZ921932, as illustrated in Figure 12. (a) Macrobrevin was detected at peak 63 at time 12.32 min with m/z 667.44. (b) Petrobactin was detected at peak 109 at time 20.82 min with m/z 717.49.

3. Discussion

Natural sources have always been a refuge when it comes to the antibiotic discovery. Soil, a good habitat for antimicrobial production, is an important origin for antimicrobial discovery as Streptomyces species isolated from the soil proved to be the source of the streptomycin antibiotic [16,21]. Previous literature highlighted the potential of antimicrobial discovery from different species of Paenibacillus [9] as well as from different soil organisms [22,23]. In the present study, Paenibacillus ehimensis was isolated from the soil collected from Jabal Al-twailat, Dahab, Egypt. The isolate exhibited a broad spectrum of antimicrobial activities as it showed activity against the standard and MDR Gram-positive and negative bacteria as well as fungi test organisms. Other studies showed a different antimicrobial spectrum [24]. A study emphasized on the antifungal and antibacterial activity exhibited by Paenibacillus polymyxa PKB1 [24]. The isolate bioactivity was assayed against Leptosphaeria maculans for the detection of antifungal activity and against E. coli for antibacterial activity [24]. Another study that isolated Paenibacillus tyrfis from a Malaysian swamp exhibited broad spectrum antimicrobial activity [25]. The isolated organism was tested against P. aeruginosa ATCC 10145, E. coli ATCC 25922, C. albicans, MRSA 700699, methicillin-sensitive S. aureus (MSSA) ATCC 29213, and vancomycin-resistant Enterococcus (VRE) ATCC 700802 and showed activity against the listed organisms [25]. Paenibacillus elgii, an isolate from soil sample located in Tianmu Mountain National Nature Reserve (Hangzhou, China), showed antifungal activity and antibacterial activity against both Gram-positive and Gram-negative bacteria [26]. Another research on Argentina isolated Paenibacillus polymyxa (P13) from fermented sausage identified an antimicrobial named polyxin, of proteinaceous nature, exhibited activity against a wide array of Gram-positive and Gram-negative bacteria [12]. Paenibacillus polymyxa NRRL B-30507 has proven to produce bacteriocin, which is proteinaceous in nature, and showed antimicrobial activity against food-borne bacteria, such as Campylobacter jejuni [27,28]. Another strain of Paenibacillus polymyxa isolated from food exhibited broad spectrum antimicrobial activity [29]. It showed activity against E. coli 0157:H7, Listeria monocytogenes (three strains, including the processing-resistant OSY-8578), S. enterica (four strains, including the multidrug-resistant DT109 and FM 12501-51), Salmonella enterica, Yersinia enterocolitica, S. aureus, and Bacillus cereus, but showed no activity against fungi. Its activity was attributed to a previously known antimicrobial polymyxin E1 (active against Gram-negative bacteria), a novel antibiotic 2,983-Da compound (active against Gram-positive bacteria), and designated as paenibacillin after purification [29]. Paenibacillin was tested and proven effective against Clostridium sporogenes, Bacillus spp., Lactobacillus spp., Leuconostoc mesenteroides, Lactococcus lactis, Listeria spp., Pediococcus cerevisiae, Streptococcus agalactiae, and S. aureus [29]. A bacteriocin-like peptide was produced from Paenibacillus ehimensis isolated from a soil sample in India [30]. Its activity was assessed against S. aureus (MTCC 1430), Listeria monocytogenes (MTCC 839), Bacillus subtilis (MTCC 121), Vibrio cholerae (MTCC 3904), P. aeruginosa (MTCC 1934), E. coli (MTCC 1610), Saccharomyces cerevisiae (MTCC 170), C. albicans (MTCC 1637), Asperigillus niger (MTCC 281), Fusarium oxysporum (MTCC 2773), and MRSA [30]. The isolate exerted activity against both Gram-positive and Gram-negative bacteria but showed no inhibition against fungi [30].
Previous studies conducted on the methods of fermentation and extraction of the selected isolate Paenibacillus ehimensis isolate MZ921932 proved to be a contributing factor that affects the antimicrobial production and spectrum of activity [31,32]. The study conducted on the antimicrobial production by Paenibacillus polymyxa PKB1 was performed by fermenting in a glucose-starch-CaCO3 (GSC) medium followed by methanol extraction [24]. The isolated Paenibacillus tyrfis from a Malaysian swamp was maintained on tryptic soy agar (TSA) at 30 °C for 3–4 days, and extraction was carried out [25]. The isolate Paenibacillus elgii from China was fermented in the fermentation medium (0.3% sucrose, 1% peptone, 0.5% NaCl, 0.3% soluble starch, pH (7.0–7.2)) at 30 °C for 24 h [26]. Extraction of the bioactive compounds was performed by n-butanol: water (1:1) twice [26]. The antimicrobial polyxin was obtained from Paenibacillus polymyxa (P13) after growth in a brain heart infusion (BHI) medium at 30 °C for 72 h [12]. Paenibacillus polymyxa NRRL B-30507 producing bacteriocin was grown in modified Kugler’s broth medium supplemented with tryptophan, alanine, and glucose at 32 °C for 40 h and, after centrifugation, the protein contents were precipitated [28]. The strain of Paenibacillus polymyxa isolated from food was grown on tryptic soy agar containing 0.6% yeast extract (TSAYE) at 30 °C for 24 h. After centrifugation, the inoculated medium was allowed to pass through a resin, and the adsorbed antimicrobial within the resin was suspended in ethanol for antimicrobial extraction [29]. Paenibacillus ehimensis isolate from India was grown in cell-free fermented nutrient broth to produce a bacteriocin-like compound for 48 h at 30 °C [30]. Isolation of the active compound was performed by incubating the fermented media with Diaion HP20 resin [30].
Paenibacillus polymyxa PKB1 was analyzed first using HPLC, and eluted fractions were then assayed for antimicrobial activity [24]. LC/MS was then performed to analyze bioactive peaks and after purification matrix-assisted laser desorption ionization–Fourier transform ion cyclotron resonance–mass spectrometry (MALDI–FTICR–MS) for confirmation of the peptide sequence. The last confirmation was performed using GC/MS to confirm the identity of each amino acid in the peptide sequence [24]. The isolated Paenibacillus tyrfis dried extract was eluted in HPLC to acquire the active fraction, and partial purification was performed using preparative HPLC [25]. The collected extract from Paenibacillus elgii isolated from China was analyzed using MCI GEL column chromatography [26]. The eluted active fraction was then purified using a preparative HPLC system. The active fraction was then dried, and amino acid analysis was performed using the advanced Marfey’s method with LC/MS. The analysis concluded that two novel active antimicrobials were produced related to the pelgipeptin family, named Pelgipeptin A and B [26]. The molecular weight of polymyxin produced from Paenibacillus polymyxa (P13) was studied by gel filtration on a Sephadex, and then, fractions were assayed for antimicrobial bioactivity [12]. Bacteriocin produced from Paenibacillus polymyxa NRRL B-30507 was purified using gel filtration method and ion exchange chromatography, followed by antimicrobial detection in eluted fractions [28]. Bacteriocins were analyzed using gel electrophoresis and isoelectrofocusing. The gel strips were then analyzed for microbial inhibition [28]. Further detection of bacteriocin was performed by amino acid sequencing using Edman degradation, and its molecular mass was determined using matrix-assisted laser desorption [28]. The extract isolated from Paenibacillus polymyxa isolated from food was purified using HPLC, and the antimicrobial fraction was collected and analyzed using LC/MS. The amino acid sequence of the antimicrobial was analyzed using MALDI-TOF MS, NMR, and MS/MS and was later identified as paenibacillin [29]. Antimicrobial fractions produced from Paenibacillus ehimensis isolated from India were purified using gel filtration chromatography and further processed using HPLC. The final product was analyzed using circular dichroism (CD), NMR, PEGylation, and MALDI [30].
Utilizing metagenomics analysis for antimicrobial discovery is a promising approach [14]. In the current study, a soil sample was collected from Jabal Al-twailat, Dahab, Egypt for analysis. The collected soil sample revealed only three isolates exhibiting different antimicrobial activities. The most promising one was the identified isolate Paenibacillus ehimensis isolate MZ921932, which showed broad spectrum antimicrobial activity as well as antifungal activity, which was uncommon to be associated with the genus Paenibacillus. Several studies analyzed soil sample using metagenomics. Analysis of the biosynthetic gene clusters (BGC) of Actinobacteria, Acidobacteriota, Verrucomicrobiota, and Gemmatimonadota found in the Mars Oasis in the Southern Maritime Antarctic showed that they were able to produce various antimicrobial metabolites [33]. A deep sequencing using Illumina HiSeq 2500 platform of Mantag Mangrove forests soil demonstrated that Proteobacteria (≅55%) was the most abundant, followed by Firmicutes (≅11%) and Bacteroidetes (≅7%). Actinobacteria, Chloroflexi, Cyanobacteria, and Planctomycetes were also present (≅3–5% each) [34]. The different microbial habitats show an opportunity for antimicrobial discovery.
AntiSMASH analysis was performed on the soil sample collected in this study for the detection of secondary metabolite gene clusters. The correlation of LC/MS analysis with the identified secondary metabolite gene clusters was proven to be an efficient method for the identification of bacterial metabolites. The gene clusters of Paenibacillus ehimensis isolate MZ921932 were targeted as they showed a promising activity against both MDR Gram-positive and Gram-negative bacteria as well as pathogenic Candida spp. Similarity between the query sequences and other pre-identified secondary metabolite gene clusters suggested several metabolites. There was a genetic similarity of 83% to a siderophore called petrobactin. Petrobactin is a low-molecular-mass iron (3)-chelating compound. Siderophore antibiotic conjugate is an approach to overcome cellular barriers; in the case of petrobactin, it is essential for iron uptake in bacteria, in which a petrobactin antibiotic conjugate can act as a Trojan horse for the antibacterial activity [35,36]. Tridecaptin showed its potential against Gram-negative bacteria with low cytotoxicity as it blocks ATP synthesis in bacteria through a lipid-II-binding motif [37,38]. A genetic similarity of 100% to β-lactones was also found. β-lactones are natural products that have been described to have potent antifungal and antibacterial activity on human cancer cell lines. Chemically, they are four-membered heterocycles with high ring-strain, electrophilicity, and reactivity [39]. A gene cluster similarity of 42% to the locillomycin producing gene cluster was also found [39]. Locillomycin was found to show moderate activity against MRSA and a significant antiviral activity with great potential for clinical use as it has low cytotoxicity [40]. A 40% gene similarity to Polymyxin A and Polymyxin B (Colistin A and Colistin B) producing genes was concluded. It is widely known that colistin is used to treat serious Gram-negative infections [41]. A gene cluster with 40% similarity to carotenoid (terpene) production of terpenes was found. Terpenes were previously associated with antimicrobial activity [42,43]. A gene cluster showed similarity to different types of polyketides, difficidin, macrobrevin, and sorangicin, with 20%, 20%, and 13% similarity, respectively. Several polyketides have several antimicrobial activities, such as rythromycins and rifamycins with different mechanisms of actions [44]. Thus, a hybrid region was also found in the gene cluster analysis with similarity to Paenibacterin, Polymyxin B, Tridecaptin, Colistin A/Colistin B, and Fengycin-producing gene clusters. The exhibited antimicrobial activity of the isolate Paenibacillus ehimensis MZ921932 is an outcome of the collective action of the identified secondary metabolites.
Compared to other studies, an isolated strain of Paenibacillus alvei, a strain related to this group, has great potential to produce antimicrobial metabolites [44]. The identified BGCs were performed using the whole genome sequencing by Illumina platform. The identified BGCs with 100% similarity were bicornutinA1/A2, paenibactin, polymyxin, paenibacterin, icosalide A/B, and anabaenopeptin NZ857 [45]. Colistin A/B, paenibacterin, tridecaptin, polymyxin B, pellasoren, marthiapeptid, and pelgipeptin genes were also identified with lower similarity. Other NRPS and hybrid cluster with less than 25% similarity or total novelty suggested new antimicrobial compounds [45]. A study that collected a soil sample from rhizosphere and tomatoes resulted in isolation of Bacillus and Paenibacillus with antagonistic activity [46]. Alongside known BGCs, such as surfactin, bacillibactin, and fengycin, novel BGCs were identified from the isolates [46]. Paenibacillus polymyxa E681 isolate from South Korea sequence revealed several BGCs including NRPS, PKSs, and bacteriocin [47]. Eleven BGCs were identification using the antiSMASH database [47].

4. Materials and Methods

4.1. Isolation and Characterization

A collection of soil samples was gathered from different localities in Egypt. For the purpose of decreasing the microbial count, the soil samples were air dried for one week in shade followed by heating for one hour at 80 °C in a hot air oven for further physical treatment [48,49]. Prepared suspensions of soil samples (1 g per 9 mL saline) were vortexed at 400 rpm for 4 min [50,51]. A series of 10-fold serial dilutions in six tubes were prepared. For every dilution, 1 mL was spread on the surface of Starch Casein Agar (SCA) [49]. Preliminary screening was performed against various bacterial isolates to determine its inhibitory effect at the end of a 7-day incubation period. Preliminary identification of soil bacteria was performed through microscopical analysis and variable biochemical tests [52,53].

4.2. Preliminary Screening

Bacterial isolates recovered from different soil samples were selected according to their antimicrobial activities against standard E. coli ATCC 25922 and clinical isolates of three vancomycin resistance S. aureus (VRSA1, VRSA2, and VSRA3), three Staphylococcus (S.) epidermidis (SE1, SE2, and SE3), two MDR E. coli (EC1 and EC2), three multidrug-resistant (MDR) K. pneumoniae (KP1, KP2, and KP3), three Candia (C.) auris (CS1, CS2, and CS3), and three C. albicans (CA1, CA2, and CA3), and the clinical isolates were discharged from the Central Microbiology Lab of Ain Shams Hospital. Table 5 represents the antimicrobial resistance patterns of the respective clinical isolates. All recovered isolates from the soil were inoculated on Mueller Hinton agar (MHA) and the test organisms were inoculated perpendicularly to the isolate [54,55]. The plates were then incubated for 24 h at 37 °C. The formation of an inhibition zone around the tested organisms indicated the antimicrobial activity of the respective isolate [54,56].

4.3. 16 S Ribosomal RNA Gene

According to results of preliminary antimicrobial screening, 16S ribosomal RNA of the most promising was sequenced and analyzed by GATC Biotech Co., Germany through Sigma Scientific Services Co., Egypt. The provided contig of the 16S ribosomal RNA was aligned and blasted in GenBank database using Basic Local Alignment Search Tool (BLAST, https://blast.ncbi.nlm.nih.gov/Blast.cgi, accessed on 5 December 2021) provided by NCBI. The result was presented as percentage homology between the query sequence and those provided by the database. Multiple Sequence Comparison by Log-Expectation (MUSCLE, https://www.ebi.ac.uk/Tools/msa/muscle/, accessed on 5 December 2021) was used to determine the alignment of the 16S ribosomal RNA sequence against the database to retrieve phylogenetic tree. Phylogenetic tree was inferred via likelihood method with a bootstrap analysis (1000 replicates). The 16S ribosomal RNA sequence was deposited in the NCBI GenBank.

4.4. Production of the Antimicrobial Metabolite(s) in Shake Flasks

Seed Culture Preparation and Growth Conditions

The seed culture was prepared by transferring a loopful of fresh culture of the promising bacterial isolate(s) into 50 mL starch casein broth and incubated at 200 rpm at 35 °C for 24 h. About one mL of the culture was centrifuged for 5 min at 16,000 rpm using a micro centrifuge tube, washed twice with 1 mL sterile saline, and used to inoculate the production flasks (100 mL of casein starch broth X 20 flasks). These flasks were incubated in a shaking incubator (150 rpm) for 7–10 days at 35 °C [57]. Centrifugation at 10,000 rpm for 10 min was performed for separation of the biomass. The filtrate was then passed through a 0.45 μm membrane filter (Merck, Darmstadt, Germany) for separation of the bacterial cells from the culture medium.

4.5. Purification of the Antimicrobial Metabolite(s)

Extraction was performed sequentially using the solvent extraction method. The solvents used were ethyl acetate and dichloromethane. Equal volumes of ethyl acetate were added first to the filtrate in a separating funnel [57]. The mixture was agitated for 2 h at 10 min intervals and left over night for complete separation. The upper organic layer was collected and stored at 4 °C for further analysis. The previous steps were repeated for dichloromethane [57]. The organic layers from ethyl acetate and dichloromethane were dried using a rotary evaporator (Buchi R205, Flawil, Switzerland) at 45 °C [56,58,59].

4.6. In Vitro Testing of the Antimicrobial Activities of the Extracted Metabolite(s)

The ethyl acetate and dichloromethane crude extracts were both dissolved in DMSO [54]. The antimicrobial testing was performed using both extracts and the filtrate left after extraction with both solvents using well diffusion method [56]. The two organic extracts were tested against eight organisms (S. aureus ATCC 25293, VRSA2, EC1, EC2, KP1, KP2, C. albicans ATCC 10231, and CA1). A negative control well was filled with DMSO [56].

4.7. Metagenomics Analysis of the Soil Samples

4.7.1. DNA Extraction and Quantification

Qiagen DNeasy power-soil kit (Cat. no. 12888-50 Qiagen, Hilden, Germany) was used for DNA extraction as per manufacturer protocol. After DNA extraction quantification of DNA was measured by Qubit fluorometer ver. 4.0 to guarantee there is enough pure genomic material before the sequencing run, 400 ng/7 μL (55 ng/μL), as mentioned by Oxford nanopore manual. Metagenomics were performed at HITS Solutions Co (Bioinformatics Department, Cairo, Egypt, http://www.hitssolutions.com/ accessed on 5 December 2021) [15].

4.7.2. Library Construction

Library construction was performed using a Rapid Sequencing Kit (Oxford Nanopore Technologies, Oxford, UK, Cat. # SQK-RAD004). Before loading on the flow cell, a total of 34 μL of sequencing Buffer and 25.5 μL of loading Beads were added to 12 μL of the DNA libraries and 4.5 μL nuclease free water. After that, priming and loading onto FLO-MIN106 flow cell was performed [15].

4.7.3. Sequencing and Data Analysis

Sequencing was run on MinION™ (Oxford Nanopore Technologies) for 12 h, which generates 3.03M reads with N50 equals 9.29K. Base calling was performed in real time during sequencing by the Guppy software. which generates FAST5 and FASTq files, and reads below Q7 were eliminated. A centrifuge was used to classify sequencing reads to a taxonomic identifier, as previously reported [60]. Results were visualized using re-centrifuged [15].

4.7.4. Genome Sequencing Aligning and Analysis

AntiSMASH version 2 (Antibiotics and Secondary Metabolite Analysis Shell) (http://antismash.secondarymetabolites.org/ accessed on 5 December 2021) was applied for the extraction of the probable secondary metabolite gene cluster of the isolate. Mauve software was used (http://gel.ahabs.wisc.edu/mauve accessed on 5 December 2021) for draft genome comparison [61].

4.8. Characterization of the Antimicrobial Metabolite(s)

4.8.1. Thin Layer Chromatography (TLC) Analysis

Preliminary separation of the metabolite(s) was performed for both ethyl acetate and dichloromethane extracts using TLC analysis. The crude extracts were spotted on separate Silica TLC coated plates 20 × 20 cm (pre-coated with silica gel 60 F254, Merck, Germany) and developed in three different solvent systems. The three solvent systems were: ethyl acetate: dichloromethane (9:1); ethyl acetate: methanol (9:1); and dichloromethane: methanol (6.5:3.5). The fractionated metabolites were observed under UV light at 254 nm (absorbance) and 365 nm (fluorescence) [62].

4.8.2. Liquid Chromatography–Mass Spectroscopy (LC/MS) Analysis

LC/MS analysis was performed at Center for Drug Discovery Research and Development, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. The analysis was performed using ESI-MS positive and negative ion acquisition mode with a XEVO TQD triple quadruple instrument, Waters Corporation, Milford, MA01757 USA, mass spectrometer. The stationary phase was a ACQUITY UPLC-BEH C18 1.7 µm-2.1 × 50 mm Column (Santa Clara, CA, USA). The mobile phase was gradient elution consisting of water containing 0.1% formic acid and acetonitrile containing 0.1% formic acid with a flow rate of 0.2 mL/min.

5. Conclusions

In conclusion, Paenibacillus ehimensis MZ921932 is a rich source for antimicrobial metabolites production that retains activities against MDR Gram-positive and Gram-negative bacteria as well as Candia. The metagenomic nanopore sequence analysis method was a rapid, easy, and efficient method for the preliminary detection of the nature of the expected active metabolites. The LC/MS spectral analysis was very helpful for further confirmation of the nature of the respective active metabolites, such as β-lactone, petrobactin, and macrobrevin. Future studies have to be conducted to purify the active metabolites and confirm their antimicrobial activities, particularly against MDR pathogens. Metagenomics analysis should be studied more for a better understanding of the microbial community and its influence in gene expression.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/antibiotics11010012/s1, Figure S1. Metagenomics analysis identifying the microbial diversity and their abundance. Figure S2. TLCs of Dichloromethane extract and Ethyl acetate extracts in different mobile phases observed under UV lamp at 365 nm (fluorescence) and 254 nm (absorbance). (a) & (b) ethyl acetate:Methanol (9:1); (c) & (d) Dichloromethane:Methanol (6.5:3.5).

Author Contributions

Conceptualization, M.A.E., W.N.E., B.T.S., I.S.Y., K.M.A. and M.S.E.A.; methodology, M.A.E., W.N.E., K.M.A. and M.S.E.A.; formal analysis, M.A.E.; writing—original draft preparation, M.A.E. and W.N.E.; writing—review and editing, M.A.E., W.N.E. and K.M.A.; supervision, W.N.E. and M.S.E.A.; funding acquisition, M.A.E., W.N.E., B.T.S. and I.S.Y. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Research Center for Advanced Materials Science (RCAMS) at King Khalid University (RCAMS/KKU/019-20) and for the Deputyship for Research and Innovation, Ministry of Education, in Saudi Arabia for funding this research work through the project number: (IFP-KKU-2020/10).

Acknowledgments

The authors express their appreciation to the Department of Microbiology, Faculty of Pharmacy, Misr International University, and to the Bioinformatics department, HITS Solutions Co., Cairo, Egypt, and to the Research Center for Advanced Materials Science (RCAMS) at King Khalid University (RCAMS/KKU/019-20). Additionally, the authors extend their appreciation to the Deputyship for Research and Innovation, Ministry of Education, in Saudi Arabia for funding this research work through the project number: (IFP-KKU-2020/10).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Smith, T. Antibiotics from soil bacteria. Nat. Struct. Mol. Biol. 2000, 7, 189–190. [Google Scholar] [CrossRef] [PubMed]
  2. Schatz, A.; Bugle, E.; Waksman, S.A. Streptomycin, a Substance Exhibiting Antibiotic Activity Against Gram-Positive and Gram-Negative Bacteria. SEBM 1944, 55, 66–69. [Google Scholar] [CrossRef]
  3. Hotchkiss, R.D.; Dubos, R.J. The isolation of bactericidal substances from cultures of Bacillus brevis. J. Biol. Chem. 1941, 141, 155–162. [Google Scholar] [CrossRef]
  4. Baltz, R.H.J.M. Antimicrobials from Actinomycetas: Back to the future. Mecrobe 2007, 2, 125–133. [Google Scholar]
  5. Katz, L.; Baltz, R.H. Natural product discovery: Past, present, and future. J. Ind. Microbiol. 2016, 43, 155–176. [Google Scholar] [CrossRef]
  6. Mülner, P.; Schwarz, E.; Dietel, K.; Herfort, S.; Jähne, J.; Lasch, P.; Cernava, T.; Berg, G.; Vater, J.J.P. Fusaricidins, Polymyxins and Volatiles Produced by Paenibacillus polymyxa Strains DSM 32871 and M1. Pathogens 2021, 10, 1485. [Google Scholar] [CrossRef] [PubMed]
  7. Ash, C.; Priest, F.G.; Collins, M.D. Molecular identification of rRNA group 3 bacilli (Ash, Farrow, Wallbanks and Collins) using a PCR probe test. Antonie Van Leeuwenhoek 1993, 64, 253–260. [Google Scholar] [CrossRef] [PubMed]
  8. Xie, J.; Shi, H.; Du, Z.; Wang, T.; Liu, X.; Chen, S. Comparative genomic and functional analysis reveal conservation of plant growth promoting traits in Paenibacillus polymyxa and its closely related species. Sci. Rep. 2016, 6, 21329. [Google Scholar] [CrossRef]
  9. Grady, E.N.; MacDonald, J.; Liu, L.; Richman, A.; Yuan, Z.-C.; Factories, M.C. Current knowledge and perspectives of Paenibacillus: A review. Microb. Cell Fact. 2016, 15, 203. [Google Scholar] [CrossRef] [Green Version]
  10. Naing, K.W.; Anees, M.; Kim, S.J.; Nam, Y.; Kim, Y.C.; Kim, K.Y. Characterization of antifungal activity of Paenibacillus ehimensis KWN38 against soilborne phytopathogenic fungi belonging to various taxonomic groups. Ann. Microbiol. 2014, 64, 55–63. [Google Scholar] [CrossRef]
  11. Singh, A.K.; Chhatpar, H.S. Purification and characterization of chitinase from Paenibacillus sp. D1. Appl. Biochem. Biotechnol. 2011, 164, 77–88. [Google Scholar] [CrossRef] [PubMed]
  12. Piuri, M.; Sanchez-Rivas, C.; Ruzal, S. A novel antimicrobial activity of a Paenibacillus polymyxa strain isolated from regional fermented sausages. Lett. Appl. Microbiol. 1998, 27, 9–13. [Google Scholar] [CrossRef] [PubMed]
  13. Land, M.; Hauser, L.; Jun, S.-R.; Nookaew, I.; Leuze, M.R.; Ahn, T.-H.; Karpinets, T.; Lund, O.; Kora, G.; Wassenaar, T.; et al. Insights from 20 years of bacterial genome sequencing. Funct. Integr. Genom. 2015, 15, 141–161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Hover, B.M.; Kim, S.-H.; Katz, M.; Charlop-Powers, Z.; Owen, J.G.; Ternei, M.A.; Maniko, J.; Estrela, A.B.; Molina, H.; Park, S.; et al. Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens. Nat. Microbiol. 2018, 3, 415–422. [Google Scholar] [CrossRef] [Green Version]
  15. Eltokhy, M.A.; Saad, B.T.; Eltayeb, W.N.; El-Ansary, M.R.; Aboshanab, K.M.; Ashour, M.S.E. A Metagenomic Nanopore Sequence Analysis Combined with Conventional Screening and Spectroscopic Methods for Deciphering the Antimicrobial Metabolites Produced by Alcaligenes faecalis Soil Isolate MZ921504. Antibiotics 2021, 10, 1382. [Google Scholar] [CrossRef] [PubMed]
  16. Hutchings, M.I.; Truman, A.W.; Wilkinson, B. Antibiotics: Past, present and future. Curr. Opin. Microbiol. 2019, 51, 72–80. [Google Scholar] [CrossRef]
  17. Wilson, M.C.; Mori, T.; Rückert, C.; Uria, A.R.; Helf, M.; Takada, K.; Gernert, C.; Steffens, U.A.E.; Heycke, N.; Schmitt, S.; et al. An environmental bacterial taxon with a large and distinct metabolic repertoire. Nat. Cell Biol. 2014, 506, 58–62. [Google Scholar] [CrossRef] [Green Version]
  18. Lincke, T.; Behnken, S.; Ishida, K.; Roth, M.; Hertweck, C. Closthioamide: An unprecedented polythioamide antibiotic from the strictly anaerobic bacterium Clostridium cellulolyticum. Angew. Chem. 2010, 122, 2055–2057. [Google Scholar] [CrossRef]
  19. Kumar, D.; Kumar, S.; Kumar, A. Extraction and characterization of secondary metabolites produced by bacteria isolated from industrial wastewater. J. Water Process. Eng. 2021, 40, 101811. [Google Scholar] [CrossRef]
  20. Meenupriya, J.; Thangaraj, M. Isolation and molecular characterization of bioactive secondary metabolites from Callyspongia spp. associated fungi. Asian Pac. J. Trop. Med. 2010, 3, 738–740. [Google Scholar] [CrossRef] [Green Version]
  21. Procópio, R.E.; Silva, I.R.; Martins, M.K.; Azevedo, J.L.; Araújo, J.M. Antibiotics produced by Streptomyces. Braz. J. Infect. Dis. 2012, 16, 466–471. [Google Scholar] [CrossRef] [Green Version]
  22. El-Sayed, S.E.; Abdelaziz, N.A.; El-Housseiny, G.S.; Aboshanab, K.M. Octadecyl 3-(3, 5-di-tert-butyl-4-hydroxyphenyl) propanoate, an antifungal metabolite of Alcaligenes faecalis strain MT332429 optimized through response surface methodology. Appl. Microbiol. Biotechol. 2020, 104, 10755–10768. [Google Scholar] [CrossRef]
  23. El-Sayed, S.E.; El-Housseiny, G.S.; Abdelaziz, N.A.; El-Ansary, M.R.; Aboshanab, K.M. Optimized Production of the Allylamine Antifungal “Terbinafine” by Lysinibacillus Isolate MK212927 Using Response Surface Methodology. Infect. Drug Resist. 2020, 13, 3613. [Google Scholar] [CrossRef] [PubMed]
  24. Shaheen, M.; Li, J.; Ross, A.C.; Vederas, J.C.; Jensen, S.E. Paenibacillus polymyxa PKB1 produces variants of polymyxin B-type antibiotics. Chem. Biol. 2011, 18, 1640–1648. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Aw, Y.-K.; Ong, K.-S.; Lee, L.-H.; Cheow, Y.-L.; Yule, C.M.; Lee, S. Newly isolated Paenibacillus tyrfis sp. nov., from Malaysian tropical peat swamp soil with broad spectrum antimicrobial activity. Front. Microbiol. 2016, 7, 219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Wu, X.-C.; Shen, X.-B.; Ding, R.; Qian, C.-D.; Fang, H.-H.; Li, O. Isolation and partial characterization of antibiotics produced by Paenibacillus elgii B69. FEMS Microbiol. Lett. 2010, 310, 32–38. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Stern, N.J.; Svetoch, E.A.; Eruslanov, B.V.; Kovalev, Y.N.; Volodina, L.I.; Perelygin, V.V.; Mitsevich, E.V.; Mitsevich, I.P.; Levchuk, V.P. Paenibacillus polymyxa purified bacteriocin to control Campylobacter jejuni in chickens. J. Food Prot. 2005, 68, 1450–1453. [Google Scholar] [CrossRef]
  28. Svetoch, E.A.; Stern, N.J.; Eruslanov, B.V.; Kovalev, Y.N.; Volodina, L.I.; Perelygin, V.V.; Mitsevich, E.V.; Mitsevich, I.P.; Pokhilenko, V.D.; Borzenkov, V.N. Isolation of Bacillus circulans and Paenibacillus polymyxa strains inhibitory to Campylobacter jejuni and characterization of associated bacteriocins. J. Food Prot. 2005, 68, 11–17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. He, Z.; Kisla, D.; Zhang, L.; Yuan, C.; Green-Church, K.B.; Yousef, A.E. Isolation and identification of a Paenibacillus polymyxa strain that coproduces a novel lantibiotic and polymyxin. Appl. Environ. Microbiol. 2007, 73, 168–178. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  30. Baindara, P.; Chaudhry, V.; Mittal, G.; Liao, L.M.; Matos, C.O.; Khatri, N.; Franco, O.L.; Patil, P.B.; Korpole, S. Characterization of the antimicrobial peptide penisin, a class Ia novel lantibiotic from Paenibacillus sp. strain A3. Antimicrob. Agents Chemother. 2016, 60, 580–591. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Fiddaman, P.; Rossall, S. Effect of substrate on the production of antifungal volatiles from Bacillus subtilis. J. Appl. Bacteriol. 1994, 76, 395–405. [Google Scholar] [CrossRef]
  32. Abouseoud, M.; Maachi, R.; Amrane, A.; Boudergua, S.; Nabi, A.J.D. Evaluation of different carbon and nitrogen sources in production of biosurfactant by Pseudomonas fluorescens. Desalination 2008, 223, 143–151. [Google Scholar] [CrossRef]
  33. Waschulin, V.; Borsetto, C.; James, R.; Newsham, K.K.; Donadio, S.; Corre, C.; Wellington, E. Biosynthetic potential of uncultured Antarctic soil bacteria revealed through long-read metagenomic sequencing. ISME J. 2021, 2021, 1–11. [Google Scholar] [CrossRef] [PubMed]
  34. Priya, G.; Lau, N.-S.; Furusawa, G.; Dinesh, B.; Foong, S.Y.; Amirul, A.-A.A. Metagenomic insights into the phylogenetic and functional profiles of soil microbiome from a managed mangrove in Malaysia. Agri Gene 2018, 9, 5–15. [Google Scholar] [CrossRef]
  35. Swayambhu, G.; Bruno, M.; Gulick, A.M.; Pfeifer, B. Siderophore natural products as pharmaceutical agents. Curr. Opin. Biotechnol. 2021, 69, 242–251. [Google Scholar] [CrossRef]
  36. Tillotson, G.S. Trojan Horse Antibiotics–A Novel Way to Circumvent Gram-Negative Bacterial Resistance? Infect. Dis. 2016, 9, 242–251. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Jangra, M.; Kaur, M.; Tambat, R.; Rana, R.; Maurya, S.K.; Khatri, N.; Ghafur, A.; Nandanwar, H. Tridecaptin M, a new variant discovered in mud bacterium, shows activity against colistin-and extremely drug-resistant Enterobacteriaceae. Antimicrob. Agents Chemother. 2019, 63, e00338-19. [Google Scholar] [CrossRef] [Green Version]
  38. Cochrane, S.; Findlay, B.; Bakhtiary, A.; Acedo, J.; Rodriguez-Lopez, E.M.; Mercier, P.; Vederas, J.C. Antimicrobial lipopeptide tridecaptin A1 selectively binds to Gram-negative lipid II. Proc. Natl. Acad. Sci. USA 2016, 113, 11561–11566. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Robinson, S.L.; Wackett, L.P. Rings of Power: Enzymatic Routes to β-Lactones. In Comprehensive Natural Products III: Chemistry and Biology, Enzymes and Enzyme Mechanisms; Elsevier: Oxford, UK, 2020; pp. 323–345. [Google Scholar] [CrossRef]
  40. Luo, C.; Liu, X.; Zhou, X.; Guo, J.; Truong, J.; Wang, X.; Zhou, H.; Li, X.; Chen, Z. Unusual biosynthesis and structure of locillomycins from Bacillus subtilis 916. Appl. Environ. Microbiol. 2015, 81, 6601–6609. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  41. Ezadi, F.; Ardebili, A.; Mirnejad, R. Antimicrobial susceptibility testing for polymyxins: Challenges, issues, and recommendations. J. Clin. Microbiol. 2019, 57, e01390-18. [Google Scholar] [CrossRef] [Green Version]
  42. Gallucci, M.N.; Oliva, M.; Casero, C.; Dambolena, J.; Luna, A.; Zygadlo, J.; Demo, M.J.F. Antimicrobial combined action of terpenes against the food—Borne microorganisms Escherichia coli, Staphylococcus aureus and Bacillus cereus. Flavour Fragr. J. 2009, 24, 348–354. [Google Scholar] [CrossRef]
  43. Mahizan, N.A.; Yang, S.-K.; Moo, C.-L.; Song, A.A.-L.; Chong, C.-M.; Chong, C.-W.; Abushelaibi, A.; Lim, S.-H.E.; Lai, K.-S. Terpene derivatives as a potential agent against antimicrobial resistance (AMR) pathogens. Molecules 2019, 24, 2631. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Robertsen, H.L.; Musiol-Kroll, E.M. Actinomycete-derived polyketides as a source of antibiotics and lead structures for the development of new antimicrobial drugs. Antibiotics 2019, 8, 157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Pranav, P.S.; Mahalakshmi, B.; Sivakumar, R.; Karthikeyan, R.; Rajendhran, J. Whole-Genome Sequence Analysis of Paenibacillus alvei JR949 Revealed Biosynthetic Gene Clusters Coding for Novel Antimicrobials. Curr. Microbiol. 2021, 78, 1168–1176. [Google Scholar] [CrossRef] [PubMed]
  46. Zhou, L.; Song, C.; Li, Z.; Kuipers, O.P. Antimicrobial activity screening of rhizosphere soil bacteria from tomato and genome-based analysis of their antimicrobial biosynthetic potential. BMC Genom. 2021, 22, 29. [Google Scholar] [CrossRef] [PubMed]
  47. Jeong, H.; Choi, S.-K.; Ryu, C.-M.; Park, S.-H. Chronicle of a soil bacterium: Paenibacillus polymyxa E681 as a tiny guardian of plant and human health. Front. Microbiol. 2019, 10, 467. [Google Scholar] [CrossRef] [Green Version]
  48. Kumar, R.R.; Jadeja, V.J. Isolation of actinomycetes: A complete approach. Int. J. Curr. Microbiol. Appl. Sci. 2016, 5, 606–618. [Google Scholar] [CrossRef] [Green Version]
  49. Jeffrey, L.S.H. Isolation, characterization and identification of actinomycetes from agriculture soils at Semongok, Sarawak. Afr. J. Biotechnol. 2008, 7, 3697–3702. [Google Scholar]
  50. Agadagba, S.K.; Bash, E.; Chitte, R.; Deshmukh, S.; Kanekar, P.; Chutipongtanate, S. Isolation of Actinomycetes from soil. J. Microbiol. Res. 2014, 4, 136–140. [Google Scholar]
  51. Yilmaz, E.I.; Yavuz, M.; Kizil, M. Molecular characterization of rhizospheric soil streptomycetes isolated from indigenous Turkish plants and their antimicrobial activity. J. Microbiol. Biotechnol. 2008, 24, 1461–1470. [Google Scholar] [CrossRef]
  52. Elston, H.R.; Baudo, J.A.; Stanek, J.P.; Schaab, M. Multi-biochemical test system for distinguishing enteric and other gram-negative bacilli. Appl. Microbiol. 1971, 22, 408–414. [Google Scholar] [CrossRef] [PubMed]
  53. Abou-Elela, G.M.; Ibrahim, H.A.; Hassan, S.W.; Abd-Elnaby, H.; El-Toukhy, N. Alkaline protease production by alkaliphilic marine bacteria isolated from Marsa-Matrouh (Egypt) with special emphasis on Bacillus cereus purified protease. Afr. J. Biotechnol. 2011, 10, 4631–4642. [Google Scholar]
  54. Arasu, M.V.; Duraipandiyan, V.; Agastian, P.; Ignacimuthu, S. In vitro antimicrobial activity of Streptomyces spp. ERI-3 isolated from Western Ghats rock soil (India). J. Mycol. Méd. 2009, 19, 22–28. [Google Scholar] [CrossRef]
  55. Iqbal, S.; Qasim, M.; Begum, F.; Begum, F.; Rahman, H. Isolation and molecular identification of Bacillus safensis (MK-12.1) exhibiting broad-spectrum antibacterial activity against multi-drug resistant isolates. J. Bacteriol. Mycol. Open Access 2021, 9, 87–92. [Google Scholar] [CrossRef]
  56. Rajaram, S.K.; Ahmad, P.; Keerthana, S.S.S.; Cressida, P.J.; Moorthy, I.G.; Suresh, R. Extraction and purification of an antimicrobial bioactive element from lichen associated Streptomyces olivaceus LEP7 against wound inhabiting microbial pathogens. J. King Saud Univ.-Sci. 2020, 32, 2009–2015. [Google Scholar] [CrossRef]
  57. Ranjan, R.; Jadeja, V. Isolation, characterization and chromatography based purification of antibacterial compound isolated from rare endophytic actinomycetes Micrococcus yunnanensis. J. Pharm. Anal. 2017, 7, 343–347. [Google Scholar] [CrossRef]
  58. Selvin, J.; Shanmughapriya, S.; Gandhimathi, R.; Kiran, G.S.; Ravji, T.R.; Natarajaseenivasan, K.; Hema, T.A. Optimization and production of novel antimicrobial agents from sponge associated marine actinomycetes Nocardiopsis dassonvillei MAD08. Appl. Microbiol. Biotechnol. 2009, 83, 435. [Google Scholar] [CrossRef]
  59. Hozzein, W.N.; Rabie, W.; Ali, M.I.A. Screening the Egyptian desert actinomycetes as candidates for new antimicrobial compounds and identification of a new desert Streptomyces strain. Afr. J. Biotechnol. 2011, 10, 2295–2301. [Google Scholar]
  60. Sanderson, N.D.; Street, T.L.; Foster, D.; Swann, J.; Atkins, B.L.; Brent, A.J.; McNally, M.A.; Oakley, S.; Taylor, A.; Peto, T.E.A.; et al. Real-time analysis of nanopore-based metagenomic sequencing from infected orthopaedic devices. BMC Genom. 2018, 19, 714. [Google Scholar] [CrossRef] [Green Version]
  61. Kapley, A.; Tanksale, H.; Sagarkar, S.; Prasad, A.; Kumar, R.A.; Sharma, N.; Qureshi, A.; Purohit, H.J. Antimicrobial activity of Alcaligenes sp. HPC 1271 against multidrug resistant bacteria. Funct. Integr. Genom. 2016, 16, 57–65. [Google Scholar] [CrossRef]
  62. Chawawisit, K.; Bhoopong, P.; Phupong, W.; Lertcanawanichakul, M. 2,4-Di-tert-butylphenol, the bioactive compound produced by Streptomyces sp. KB1. J. Appl. Pharm. Sci. 2015, 5, 7–12. [Google Scholar]
Antibiotics 11 00012 g001 550
Figure 1. Gene arrangement of siderophore petrobactin gene cluster homologous to query sequence of Paenibacillus ehimensis isolate MZ921932 to query sequence. Putative biosynthetic genes presented in red, additional biosynthetic genes in orange, transport-related genes in blue, regulation-related genes in green, resistance genes in pink, and TTA codon in dark pink; grey represent other genes.
Figure 1. Gene arrangement of siderophore petrobactin gene cluster homologous to query sequence of Paenibacillus ehimensis isolate MZ921932 to query sequence. Putative biosynthetic genes presented in red, additional biosynthetic genes in orange, transport-related genes in blue, regulation-related genes in green, resistance genes in pink, and TTA codon in dark pink; grey represent other genes.
Antibiotics 11 00012 g001
Antibiotics 11 00012 g002 550
Figure 2. Gene arrangement of Tridecaptin gene cluster homologous to query sequence of Paenibacillus ehimensis isolate MZ921932 to query sequence. Putative biosynthetic genes presented in red, transport-related genes in blue, and regulation-related genes in green.
Figure 2. Gene arrangement of Tridecaptin gene cluster homologous to query sequence of Paenibacillus ehimensis isolate MZ921932 to query sequence. Putative biosynthetic genes presented in red, transport-related genes in blue, and regulation-related genes in green.
Antibiotics 11 00012 g002
Antibiotics 11 00012 g003 550
Figure 3. Gene arrangement of β-lactone gene cluster homologous to query sequence of Paenibacillus ehimensis isolate MZ921932 to query sequence. Putative biosynthetic genes presented in red, additional biosynthetic genes in orange, transport-related genes in blue, regulation-related genes in green, resistance genes in pink, and TTA codon in dark pink; grey represents other genes.
Figure 3. Gene arrangement of β-lactone gene cluster homologous to query sequence of Paenibacillus ehimensis isolate MZ921932 to query sequence. Putative biosynthetic genes presented in red, additional biosynthetic genes in orange, transport-related genes in blue, regulation-related genes in green, resistance genes in pink, and TTA codon in dark pink; grey represents other genes.
Antibiotics 11 00012 g003
Antibiotics 11 00012 g004 550
Figure 4. Gene arrangement of Locillomycin gene cluster homologous to query sequence of Paenibacillus ehimensis isolate MZ921932 to query sequence. Putative biosynthetic genes presented in red, additional biosynthetic genes in orange, transport-related genes in blue, regulation-related genes in green, resistance genes in pink, and TTA codon in dark pink; grey represents other genes.
Figure 4. Gene arrangement of Locillomycin gene cluster homologous to query sequence of Paenibacillus ehimensis isolate MZ921932 to query sequence. Putative biosynthetic genes presented in red, additional biosynthetic genes in orange, transport-related genes in blue, regulation-related genes in green, resistance genes in pink, and TTA codon in dark pink; grey represents other genes.
Antibiotics 11 00012 g004
Antibiotics 11 00012 g005 550
Figure 5. Gene arrangement of Polymyxin gene cluster homologous to query sequence of Paenibacillus ehimensis isolate MZ921932 to query sequence. Putative biosynthetic genes presented in red, additional biosynthetic genes in orange, transport-related genes in blue, regulation-related genes in green, resistance genes in pink, and TTA codon in dark pink; grey represents other genes.
Figure 5. Gene arrangement of Polymyxin gene cluster homologous to query sequence of Paenibacillus ehimensis isolate MZ921932 to query sequence. Putative biosynthetic genes presented in red, additional biosynthetic genes in orange, transport-related genes in blue, regulation-related genes in green, resistance genes in pink, and TTA codon in dark pink; grey represents other genes.
Antibiotics 11 00012 g005
Antibiotics 11 00012 g006 550
Figure 6. Gene arrangement of Carotenoid terpene gene cluster homologous to query sequence of Paenibacillus ehimensis isolate MZ921932 to query sequence. Putative biosynthetic genes presented in red, additional biosynthetic genes in orange, transport-related genes in blue, regulation-related genes in green, resistance genes in pink, and TTA codon in dark pink; grey represents other genes.
Figure 6. Gene arrangement of Carotenoid terpene gene cluster homologous to query sequence of Paenibacillus ehimensis isolate MZ921932 to query sequence. Putative biosynthetic genes presented in red, additional biosynthetic genes in orange, transport-related genes in blue, regulation-related genes in green, resistance genes in pink, and TTA codon in dark pink; grey represents other genes.
Antibiotics 11 00012 g006
Antibiotics 11 00012 g007 550
Figure 7. Gene arrangement of polyketide gene cluster homologous to query sequence of Paenibacillus ehimensis isolate MZ921932 to query sequence. Putative biosynthetic genes presented in red, additional biosynthetic genes in orange, transport-related genes in blue, regulation-related genes in green, resistance genes in pink, and TTA codon in dark pink; grey represents other genes.
Figure 7. Gene arrangement of polyketide gene cluster homologous to query sequence of Paenibacillus ehimensis isolate MZ921932 to query sequence. Putative biosynthetic genes presented in red, additional biosynthetic genes in orange, transport-related genes in blue, regulation-related genes in green, resistance genes in pink, and TTA codon in dark pink; grey represents other genes.
Antibiotics 11 00012 g007
Antibiotics 11 00012 g008 550
Figure 8. Gene arrangement of polymyxin gene cluster homologous to query sequence of Paenibacillus ehimensis isolate MZ921932 to query sequence. Putative biosynthetic genes presented in red, transport-related genes in blue, regulation-related genes in green, resistance genes in pink, and TTA codon in dark pink; grey represents other genes.
Figure 8. Gene arrangement of polymyxin gene cluster homologous to query sequence of Paenibacillus ehimensis isolate MZ921932 to query sequence. Putative biosynthetic genes presented in red, transport-related genes in blue, regulation-related genes in green, resistance genes in pink, and TTA codon in dark pink; grey represents other genes.
Antibiotics 11 00012 g008
Antibiotics 11 00012 g009 550
Figure 9. A cell-free ethyl acetate extract run on both ESI-MS positive and negative ion mode for antibiotic detection from the isolate Paenibacillus ehimensis isolate MZ921932 using XEVO TQD triple quadrupole instrument.
Figure 9. A cell-free ethyl acetate extract run on both ESI-MS positive and negative ion mode for antibiotic detection from the isolate Paenibacillus ehimensis isolate MZ921932 using XEVO TQD triple quadrupole instrument.
Antibiotics 11 00012 g009
Antibiotics 11 00012 g010a 550Antibiotics 11 00012 g010b 550
Figure 10. LC/MS analysis of a cell-free ethyl acetate extract of Paenibacillus ehimensis isolate MZ921932 detection of (a) β-lactone, (b) petrobactin, and (c) macrobrevin.
Figure 10. LC/MS analysis of a cell-free ethyl acetate extract of Paenibacillus ehimensis isolate MZ921932 detection of (a) β-lactone, (b) petrobactin, and (c) macrobrevin.
Antibiotics 11 00012 g010aAntibiotics 11 00012 g010b
Antibiotics 11 00012 g011a 550Antibiotics 11 00012 g011b 550
Figure 11. A cell-free dichloromethane extract run on both ESI-MS positive and negative ion mode for antibiotic detection from the isolate Paenibacillus ehimensis isolate MZ921932 using XEVO TQD triple quadrupole instrument.
Figure 11. A cell-free dichloromethane extract run on both ESI-MS positive and negative ion mode for antibiotic detection from the isolate Paenibacillus ehimensis isolate MZ921932 using XEVO TQD triple quadrupole instrument.
Antibiotics 11 00012 g011aAntibiotics 11 00012 g011b
Antibiotics 11 00012 g012a 550Antibiotics 11 00012 g012b 550
Figure 12. LC/MS analysis of a cell-free dichloromethane extract of Paenibacillus ehimensis isolate MZ921932. Detection of (a) macrobrevin and (b) petrobactin.
Figure 12. LC/MS analysis of a cell-free dichloromethane extract of Paenibacillus ehimensis isolate MZ921932. Detection of (a) macrobrevin and (b) petrobactin.
Antibiotics 11 00012 g012aAntibiotics 11 00012 g012b
Table
Table 1. Preliminary screening against Gram-positive test organisms.
Table 1. Preliminary screening against Gram-positive test organisms.
Isolate CodeGram Positive Test Organisms
SE1SE2SE3VRSA1VRSA2VRSA3
SP1 ++++++
SP2 ++++++
SP3------
+: inhibits growth, -: no inhibition and.SE1, S. epidermidis isolate 1; SE2, S. epidermidis isolate 2; SE3, S. epidermidis isolate 3; VRSA1, vancomycin resistance S. aureus isolate 1; VRSA2, vancomycin resistance S. aureus isolate 2; VSRA3, vancomycin resistance S. aureus isolate 3.
Table
Table 2. Preliminary screening against Gram-negative test organisms.
Table 2. Preliminary screening against Gram-negative test organisms.
Isolate CodeGram Negative Test Organisms
E. coli ATCC 25922EC1EC2KP1KP2KP3
SP1++++++
SP2------
SP3---±--
+: inhibits growth, -: no inhibition and ±: partial inhibition. EC1, MDR E. coli isolate 1; EC2; MDR E. coli isolate 2; KP1, MDR K. pneumoniae isolate 1; KP2, MDR K. pneumoniae isolate 2; KP3, MDR K. pneumoniae isolate 3.
Table
Table 3. Preliminary screening against tested Candida spp.
Table 3. Preliminary screening against tested Candida spp.
Isolate CodeCandida spp. Test Organisms
CA1CA2CA3CS1CS2CS3
SP1++++++
SP2--++++
SP3±--±--
+: complete inhibition; -: no inhibition; ±: partial inhibition; CA1, C. albicans isolate 1; CA2, C. albicans isolate 2; CA3, C. albicans isolate 3; CS1, C. auris isolate 1; CS2, C. auris isolate 2; CS3, C. auris isolate 3.
Table
Table 4. The antimicrobial activity of the solvent extracts of Paenibacillus ehimensis isolate MZ921932.
Table 4. The antimicrobial activity of the solvent extracts of Paenibacillus ehimensis isolate MZ921932.
Test Organisms Mean Zone of Inhibition (mm) ± SD
Dichloromethane ExtractEthyl Acetate
Extract
S. aureus ATCC 2529319 ± 1.013 ± 0.5
VRSA215 ± 0.513 ± 1.0
KP120 ± 1.011 ± 1.0
KP214 ± 1.014 ± 0.5
EC113 ± 0.513 ± 0.5
EC214 ± 0.513 ± 0.5
C. albicans ATCC 1023111 ± 0.514 ± 1.0
CA111 ± 1.0-
-, absence of inhibition zone. VRSA2, vancomycin resistance S. aureus isolate 2; EC1, MDR E. coli isolate 1; EC2; MDR E. coli isolate 2; KP1, MDR K. pneumoniae isolate 1; KP2, MDR K. pneumoniae isolate 2; CA1, C. albicans clinical isolate 1.
Table
Table 5. Antimicrobial resistance profile of the bacterial clinical isolates.
Table 5. Antimicrobial resistance profile of the bacterial clinical isolates.
Gram-PositiveGram-Negative
Clinical Isolate CodeResistance PatternClinical Isolate CodeResistance Pattern
SE1, SE2, SE3CLI, CN, FOX, CIPKP1AMC, ATM, CTX, CAZ, CRO, FEP, CIP, SXT, TET, IMP, ETP, DOR, CT, PB, FF, RA, CN
VRSA1VAN, FOXKP2AK, AMC, ATM, CTX, CAZ, CRO, FEP, CIP, SXT, TET, IMP, ETP, DOR, CT, FF, RA, CN
VRSA2, VSRA3VAN, CLI, CN, FOX, CIPKP3AK, AMC, ATM, CTX, CAZ, CRO, FEP, CIP, SXT, TET, IMP, ETP, DOR, FF, RA, CN
EC1CTX, IMP
EC2AK, AMC, ATM, CTX, CAZ, CRO, FEP, CIP, SXT, TET, IMP, ETP, DOR, FF, RA,
Glycopeptides: VAN = vancomycin, Macrolides: CLI = clindamycin Beta-lactams: AMC = Amoxicillin/clavulanic ATM = Aztreonam FOX = cefoxitin CTX = Cefotaxime CAZ = Ceftazidime CRO = Ceftriaxone FEP = Cefepime DOR = Doripenem ETP = Ertapenem IMP = Imipenem; Aminoglycoside: AK = Amikacin CN = Gentamicin Quinolones: CIP = Ciprofloxacin Polymyxins: CT = Colistin PB = Polymyxin B; Sulfonamides/Diaminopyrimidine: SXT = Sulfamethoxazole/Trimethoprim Tetracyclines: TE = Tetracycline; TGC = Tigecycline Phosphonic acid derivative: FF = Fosfomycin Rifamycins: RA = Rifamycin.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Eltokhy, M.A.; Saad, B.T.; Eltayeb, W.N.; Yahia, I.S.; Aboshanab, K.M.; Ashour, M.S.E. Exploring the Nature of the Antimicrobial Metabolites Produced by Paenibacillus ehimensis Soil Isolate MZ921932 Using a Metagenomic Nanopore Sequencing Coupled with LC-Mass Analysis. Antibiotics 2022, 11, 12. https://doi.org/10.3390/antibiotics11010012

AMA Style

Eltokhy MA, Saad BT, Eltayeb WN, Yahia IS, Aboshanab KM, Ashour MSE. Exploring the Nature of the Antimicrobial Metabolites Produced by Paenibacillus ehimensis Soil Isolate MZ921932 Using a Metagenomic Nanopore Sequencing Coupled with LC-Mass Analysis. Antibiotics. 2022; 11(1):12. https://doi.org/10.3390/antibiotics11010012

Chicago/Turabian Style

Eltokhy, Mohamed A., Bishoy T. Saad, Wafaa N. Eltayeb, Ibrahim S. Yahia, Khaled M. Aboshanab, and Mohamed S. E. Ashour. 2022. "Exploring the Nature of the Antimicrobial Metabolites Produced by Paenibacillus ehimensis Soil Isolate MZ921932 Using a Metagenomic Nanopore Sequencing Coupled with LC-Mass Analysis" Antibiotics 11, no. 1: 12. https://doi.org/10.3390/antibiotics11010012

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop